Skip to main content

Onena Medicines closes 3.7M CHF funding round to advance its novel DSIP targeting antibody portfolio.

Onena Medicines AG, a cellular reprogramming platform drug discovery company, announced today the closing of a new 3.7M CHF financing round to accelerate the development of its growing Dual SMAD Inhibiting Protein (DSIP) modulating antibody portfolio. DSIPs are a novel class of targets that have breakthrough potential through their potent cellular programming effects on the proliferation and specialization of cells. The funding round consisted of private investments from Avanteca Partners and the Zürcher Kantonalbank into Onena, a BaseLaunch portfolio company. Onena was also awarded a competitive Torres Quevedo grant from the CDTI in Spain to enhance their antibody platform technologies.

We are thrilled to be backed by Avanteca Partners and the Zürcher Kantonalbank as we build Onena Medicines’ first-in-class pipeline of anti-DSIP antibody therapies. Our partners realize, as we do, the incredible opportunity that lies before us to lead the AI drug discovery field.

Neethan LoboCEO and Co-Founder of Onena Medicines

Read the official press release here.

Share this article

View all news

Sign up to receive our newsletter in your inbox.